Bitterman Robert J

Chairman, Pres. & CEO

Bitterman Robert J has filed 11 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2025. 10 of those filings fall inside the rolling window. Most recent filing: Sep 29, 2026.

On the most recent filing, Bitterman Robert J is listed as Chairman, Pres. & CEO at Phio Pharmaceuticals Corp. Inside the rolling window, Bitterman Robert J reported 7 open-market purchases totaling $45K in PHIO and no open-market sales. The largest disclosed transaction in the window is a purchase of 10,000 PHIO shares on Aug 18, 2026, worth $11K.

Companies traded

Other insiders at PHIO

Insider Buying

$45K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PHIOPurchase$2KSep 23SEC ↗
PHIOPurchase$11KAug 19SEC ↗
PHIOPurchase$10KJun 29SEC ↗
PHIOPurchase$5KJan 2SEC ↗
PHIOPurchase$5KDec 29SEC ↗
PHIOPurchase$6KNov 24SEC ↗
PHIOPurchase$6KNov 19SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Bitterman Robert J made?

Bitterman Robert J has filed 11 SEC Form 4 filings (12 transaction rows) across 1 company since 2025.

Which companies does Bitterman Robert J trade?

Bitterman Robert J has filed SEC Form 4 disclosures for 1 company, including PHIO.

When was Bitterman Robert J's most recent SEC Form 4 filing?

Bitterman Robert J's most recent SEC Form 4 filing on Tracefour is dated Sep 29, 2026.

What is Bitterman Robert J's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Bitterman Robert J is listed as Chairman, Pres. & CEO.

What is Bitterman Robert J's total buy and sell value in the current window?

Inside the rolling retention window, Bitterman Robert J bought $45K and sold $0 based on SEC Form 4 filings.

What was Bitterman Robert J's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 10,000 PHIO shares on 2026-08-18, worth $11K, per SEC Form 4 filings.